Last reviewed · How we verify
Tetanus Day 1
At a glance
| Generic name | Tetanus Day 1 |
|---|---|
| Also known as | Tetansu Toxoid, Tetanus Toxoid Adsorbed. |
| Sponsor | Providence Health & Services |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PHASE1, PHASE2)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (PHASE1)
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection (PHASE1)
- Maternal Determinants of Infant Immunity to Pertussis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |